880150 | 14:0 PEG2000 PE
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt)

14:0 PEG2000 PE
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt)
14:0 PEG2000 PE
14:0 PEG2000 PE, also known as 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt), is a polyethylene glycol (PEG)-phospholipid conjugate in the polymerizable lipid category. It plays a pivotal role in vesicle formulation by preventing aggregation from peptide addition, which ensures stable and functional vesicles.
Application
14:0 PEG2000 PE is instrumental in the preparation and formation of giant vesicles, enabling researchers to explore cellular processes and membrane dynamics precisely and accurately. Additionally, incorporating 14:0 PEG2000 PE in lipid nanoparticle formulations enhances stability and efficacy, facilitating advanced drug delivery systems.
It has also been used to prepare unilamellar liposomes for small-angle X-ray scattering (SAXS) experiments, helping investigate molecular structures and interactions with greater clarity and detail.
Solubility
Soluble in ethanol, DMSO, and chloroform-methanol at 5mg/mL.
Packaging
Avanti Research offers 14:0 PEG2000 PE in 25 mg, 200 mg, 500 mg, and 1 g powder packaging options. With over 50 years in business, Avanti Research is the trusted leader in lipid-based products that save and improve lives. We are the premier choice for polymerizable lipids for research and development purposes
Interested in GMP-grade?
For GMP-certified versions of this phospholipid and others, visit Croda Pharma to explore their selection of pharmaceutical-grade products tailored for clinical research and commercial-scale production.
C125H251N2O55P (average MW due to polydispersity of PEG)
C 55.74%, H 9.39%, N 1.04%, O 32.67%, P 1.15%
CAS Registry Number is a Registered Trademark of the American Chemical Society
730150
Lou G, Anderluzzi G, Tandrup Schmidt S, Woods S, Gallorini S, Brazzoli M, Giusti F, Ferlenghi I, Johnson R, Roberts CW, O'Hagan DT, Baudner BC, Perrie Y. Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection. J Control Release. 2020 Jun 30:S0168-3659(20)30362-X. doi: 10.1016/j.jconrel.2020.06.027. Epub ahead of print. PMID: 32619745.
PubMed ID: 32619745Leboeuf D, Abakumova T, Prikazchikova T, Rhym L, Anderson DG, Zatsepin TS, Piatkov KI. Downregulation of the Arg/N-degron Pathway Sensitizes Cancer Cells to Chemotherapy In Vivo. Mol Ther. 2020 Jan 21:S1525-0016(20)30053-8. doi: 10.1016/j.ymthe.2020.01.021. Epub ahead of print. PMID: 32087767.
PubMed ID: 32087767Lone A, Thomsen TT, Nielsen JE, Thulstrup PW, Klitgaard RN, Løbner-Olesen A, Lund R, Jenssen H, Hansen PR. Structure-Activity Study of an All-d Antimicrobial Octapeptide D2D. Molecules. 2019 Dec 13;24(24):4571. doi: 10.3390/molecules24244571. PMID: 31847173; PMCID: PMC6943423.
PubMed ID: 31847173Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene. 2019 Aug;38(33):6095-6108. doi: 10.1038/s41388-019-0862-y. Epub 2019 Jul 9.
PubMed ID: 31289363Nielsen JE, Lind TK, Lone A, Gerelli Y, Hansen PR, Jenssen H, Cárdenas M, Lund R. A biophysical study of the interactions between the antimicrobial peptide indolicidin and lipid model systems. Biochim Biophys Acta Biomembr. 2019 Apr 9;1861(7):1355-1364. doi: 10.1016/j.bbamem.2019.04.003. [Epub ahead of print]
PubMed ID: 30978313Callegari E, Domenicali M, Shankaraiah RC, D'Abundo L, Guerriero P, Giannone F, Baldassarre M, Bassi C, Elamin BK, Zagatti B, Ferracin M, Fornari F, Altavilla G, Blandamura S, Silini EM, Gramantieri L, Sabbioni S, Negrini M. MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. Mol Ther Nucleic Acids. 2019 Mar 1;14:239-250. doi: 10.1016/j.omtn.2018.11.018. Epub 2018 Dec 6.
PubMed ID: 30641476- Certificate of Analysis (Lot No. 880150P-1G-A-042 and 6297PQA042)
- Certificate of Analysis (Lot No. 880150P-200MG-A-042 and 6297PNA042)
- Certificate of Analysis (Lot No. 880150P-25MG-A-042 and 6297PJA042)
- Certificate of Analysis (Lot No. 880150P-500MG-A-042 and 6297PPA042)
- Certificate of Analysis (Lot No. 880150P-1G-B-042 and 6297PQB042)
- Certificate of Analysis (Lot No. 880150P-200MG-B-042 and 6297PNB042)
- Certificate of Analysis (Lot No. 880150P-500MG-B-042 and 6297PPB042)
- Certificate of Analysis (Lot No. 880150P-25MG-B-042 and 6297PJB042)
- Certificate of Analysis (Lot No. 880150P-25MG-C-042 and 6297PJC042)
- Certificate of Analysis (Lot No. 880150P-200MG-A-043 and 6297PNA043)
- Certificate of Analysis (Lot No. 880150P-25MG-A-043 and 6297PJA043)
- Certificate of Analysis (Lot No. 880150P-200MG-B-043 and 6297PNB043)
- Certificate of Analysis (Lot No. 880150P-25MG-B-043 and 6297PJB043)
- Certificate of Analysis (Lot No. 880150P-200MG-C-043 and 6297PNC043)
- Certificate of Analysis (Lot No. 880150P-25MG-C-043 and 6297PJC043)
- Certificate of Analysis (Lot No. 880150P-1G-A-043 and 6297PQA043)
- Certificate of Analysis (Lot No. 880150P-1G-A-044 and 6297PQA044)
- Certificate of Analysis (Lot No. 880150P-25MG-D-043 and 6297PJD043)
- Certificate of Analysis (Lot No. 880150P-500MG-A-044 and 6297PPA044)
- Certificate of Analysis (Lot No. 880150P-25MG-A-044 and 6297PJA044)
- Certificate of Analysis (Lot No. 880150P-500MG-B-044 and 6297PPB044)
- Certificate of Analysis (Lot No. 880150P-200MG-A-044 and 6297PNA044)
- Certificate of Analysis (Lot No. 880150P-25MG-B-044 and 6297PJB044)
- Certificate of Analysis (Lot No. 880150P-500MG-C-044 and 6297PPC044)
- Certificate of Analysis (Lot No. 880150P-200MG-B-044 and 6297PNB044)
- Certificate of Analysis (Lot No. 880150P-200MG-C-044 and 6297PNC044)
- Certificate of Analysis (Lot No. 880150P-25MG-E-044 and 6297PJE044)
- Certificate of Analysis (Lot No. 880150P-25MG-D-044 and 6297PJD044)
- Certificate of Analysis (Lot No. 880150P-500MG-D-044 and 6297PPD044)
- Certificate of Analysis (Lot No. 880150P-200MG-E-044 and 6297PNE044)
- Certificate of Analysis (Lot No. 880150P-25MG-F-044 and 6297PJF044)
- Certificate of Analysis (Lot No. 880150P-1G-B-044 and 6297PQB044)
- Certificate of Analysis (Lot No. 880150P-200MG-F-044 and 6297PNF044)
- Certificate of Analysis (Lot No. 880150P-25MG-G-044 and 6297PJG044)
- Certificate of Analysis (Lot No. 880150P-500MG-E-044 and 6297PPE044)
- Certificate of Analysis (Lot No. 880150P-1G-D-044 and 6297PQD044)
- Certificate of Analysis (Lot No. 880150P-500MG-F-044 and 6297PPF044)
- Certificate of Analysis (Lot No. 880150P-200MG-H-044 and 6297PNH044)
- Certificate of Analysis (Lot No. 880150P-25MG-I-044 and 6297PJI044)
- Certificate of Analysis (Lot No. 880150P-1G-E-044 and 6297PQE044)
- Certificate of Analysis (Lot No. 880150P-1G-F-044 and 6297PQF044)
- Certificate of Analysis (Lot No. 880150P-25MG-M-044 and 6297PJM044)
- Certificate of Analysis (Lot No. 880150P-1G-A-045 and 6297PQA045)
- Certificate of Analysis (Lot No. 880150P-25MG-J-044 and 6297PJJ044)
- Certificate of Analysis (Lot No. 880150P-25MG-K-044 and 6297PJK044)
- Certificate of Analysis (Lot No. 880150P-200MG-B-045 and 6297PNB045)
- Certificate of Analysis (Lot No. 880150P-500MG-A-045 and 6297PPA045)
- Certificate of Analysis (Lot No. 880150P-25MG-L-044 and 6297PJL044)
- Certificate of Analysis (Lot No. 880150P-500MG-B-045 and 6297PPB045)
- Certificate of Analysis (Lot No. 880150P-25MG-N-044 and 6297PJN044)
- Certificate of Analysis (Lot No. 880150P-200MG-C-045 and 6297PNC045)
- Certificate of Analysis (Lot No. 880150P-25MG-A-045 and 6297PJA045)
- Certificate of Analysis (Lot No. 880150P-25MG-B-045 and 6297PJB045)
- Certificate of Analysis (Lot No. 880150P-200MG-D-045 and 6297PND045)
- Certificate of Analysis (Lot No. 880150P-25MG-C-045 and 6297PJC045)